Mesa Laboratories Inc

Mesa Laboratories Inc(MLAB)股票分析

$125.160

+1.877 (+1.50%)收盤時

Loading chart…
最高
128.270
開盤
123.250
成交量加權均價
125.32
成交量
77.22K
市值
458.17M
最低
122.520
成交金額
9.68M
企業價值/稅息折舊攤銷前利潤(TTM)
13.93

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

AI 分析 of Mesa Laboratories Inc (MLAB)

持有

Mesa Laboratories Inc is currently a hold. The stock's price is at $122.48, which is down 3.94% over the last five days and 19.5% since its last earnings report. While the company has shown a year-to-date increase of 54.20%, the recent drop in share price and an RSI of 30.705 suggest it may be oversold, but caution is warranted due to mixed earnings results and a forward P/E ratio of 34.48, indicating high valuation risks.

分析師評級(2)

-20.90% 下跌空間
買進
1 買進
1 持有
0 賣出
目前: 125.16
最低
83.00
平均
99.00
最高
115.00

Wells Fargo

2026-02-04

目標價

$94

Equal Weight

Wells Fargo

2025-12-15

目標價

$83

Equal Weight

Jefferies

2025-11-07

目標價

$115

買進

Wells Fargo

2025-08-07

目標價

$67

Equal Weight

Wells Fargo

2025-05-30

目標價

$100

減持

估值指標

Mesa Laboratories Inc(MLAB)目前預期本益比為 34.48,5 年平均預期本益比為 30.01。

預期本益比

合理
5 年均值 P/E
30.01
目前P/E
34.48
高估
44.90
低估
15.11

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
18.68
目前EV/EBITDA
13.93
高估
28.27
低估
9.08

預期股價營收比

合理
5 年均值 P/S
3.25
目前P/S
2.55
高估
4.86
低估
1.65

Alphio AI 對 MLAB 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MLAB

$100.37

情境價格

基

基準

基準 · 50%MLAB

$97.94

情境價格

悲

悲觀

悲觀 · 25%MLAB

$84.63

情境價格

持有 MLAB 的大戶

R

Ranger Investment Management, L.P.

+ 持有MLAB

-9.37%

3個月報酬率

事件時間軸

2026-10-13 (ET)

08:30:00

Mesa Labs Announces Savings Plan to Cut Annual Operating Costs by $9.3M

2026-08-10 (ET)

16:30:00

Mesa Q1 Revenue at $60.14M, Below Consensus

2026-05-27 (ET)

08:10:00

Mesa Q1 Revenue at $63.72M, Below Consensus

2026-03-09 (ET)

16:40:00

Mesa Labs Appoints Siddhartha Kadia as New CEO

2026-02-03 (ET)

08:10:00

Mesa Reports Q3 Revenue of $65.126M, Beating Consensus

資訊

MLAB 常見問題 —— 由 Alphio AI 解答

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Mesa Laboratories Inc is currently a hold. The stock's price is at $122.48, which is down 3.94% over the last five days and 19.5% since its last earnings report. While the company has shown a year-to-date increase of 54.20%, the recent drop in share price and an RSI of 30.705 suggest it may be oversold, but caution is warranted due to mixed earnings results and a forward P/E ratio of 34.48, indicating high valuation risks.

2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易